

Neuropeptide Y Biochemical

Neuropeptide Y (human)(TFA)

CATALOG #
AAA227161


PRODUCT SYNONYMS

Neuropeptide Y; Neuropeptide Y (human)(TFA); Neuropeptide Y biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	It is showed that Neuropeptide Y (human) is able to protect cortical neurons from Abeta25-35 toxicity. 2 uM NPY abolishes the toxic effects of Abeta25-35 at 24 and 48 h. The same effect on neuronal survival is observed in neurons exposed to 1 uM and 0.5 uM Neuropeptide Y (human) pretreatments. Pretreatment with Neuropeptide Y (29-64), amide, human (TFA) Increases NGF Synthesis, reduces NGF mRNA, and restores NGF release in cortical neurons exposed to Abeta35-25[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Lys-Nepsilon-SPDB-DM4, CAS 1280215-91-9



Structure
Lys-Nepsilon-SPDB-DM4, CAS 1280215-91-9

ADDITIONAL INFORMATION

Related Product Information for Neuropeptide Y biochemical	Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against beta-Amyloid toxicity.
References	1. Hans K Erickson, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006 Apr 15;66(8):4426-33.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.